Ellagic acid inhibits human colon cancer HCT-116 cells by regulating long noncoding RNAs

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The natural phenolic compound ellagic acid exerts anti-cancer effects, including activity against colorectal cancer (CRC). Previously, we reported that ellagic acid can inhibit the proliferation of CRC, and can induce cell cycle arrest and apoptosis. This study investigated ellagic acid-mediated anticancer effects using the human colon cancer HCT-116 cell line. After 72 h of ellagic acid treatment, a total of 206 long noncoding RNAs (lncRNAs) with differential expression greater than 1.5-fold were identified (115 down-regulated and 91 up-regulated). Furthermore, the co-expression network analysis of differentially expressed lncRNA and mRNA showed that differential expressed lncRNA might be the target of ellagic acid activity in inhibiting CRC.

Cite

CITATION STYLE

APA

Zhao, J., Li, G., Ren, Y., Zhang, Z., Chen, H., Zhang, H., … Liu, M. (2023). Ellagic acid inhibits human colon cancer HCT-116 cells by regulating long noncoding RNAs. Anti-Cancer Drugs, 34(10), 1112–1121. https://doi.org/10.1097/CAD.0000000000001513

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free